An investigation for investors in NASDAQ:TRVN shares over potential securities laws violations by Trevena Inc was announced and NASDAQ:TRVN stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/21/2017 -- An investigation was announced for investors of Trevena Inc (NASDAQ:TRVN) shares over potential securities laws violations by Trevena Inc and certain of its directors and officers.
Investors who purchased shares of Trevena Inc (NASDAQ:TRVN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Trevena Inc (NASDAQ:TRVN) concerning whether a series of statements by Trevena Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On February 21, 2017, Trevena Inc announced the clinical trial results for its morphine-alternative drug, Oliceridine, which revealed that the drug did not have statistically significant rates of higher tolerability or safety as compared to standard morphine.
Shares of Trevena Inc (NASDAQ:TRVN) closed on March 20, 2017 at $3.59 per share.
Those who purchased shares of Trevena Inc have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com